Alx oncology reports first quarter 2025 financial results and provides corporate update

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at r&d day in march, company is on track to initiate phase 2 aspen-breast and phase 1 aspen-crc studies in mid-2025 ind clearance received from u.s. fda for novel egfr-targeted antibody-drug conjugate (adc), alx2004, paving way for mid-year clinical program initiation; company to host webcast focused on alx2004 research program on may 20 company will not pursue u.s. registrational path in gastric cancer following receipt of fda feedback that accelerated approval pathway is not feasible based on aspen-06 due to standard-of-care evolving to enhertu® data milestones expected across company's three clinical programs in 2026 cash runway has been extended into q4 2026 south san francisco, calif., may 08, 2025 (globe newswire) --  alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the first quarter ended march 31, 2025, and provided a corporate update.
ALXO Ratings Summary
ALXO Quant Ranking